NASDAQ:VINC - Vincerx Pharma Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $26.67
  • Forecasted Upside: 233.33 %
  • Number of Analysts: 6
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 6 Buy Ratings
  • 0 Strong Buy Ratings
$8.00
▲ +0.1 (1.27%)

This chart shows the closing price for VINC by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Vincerx Pharma Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for VINC and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for VINC

Analyst Price Target is $26.67
▲ +233.33% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for Vincerx Pharma in the last 3 months. The average price target is $26.67, with a high forecast of $30.00 and a low forecast of $24.00. The average price target represents a 233.33% upside from the last price of $8.00.

This chart shows the closing price for VINC for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 6 investment analysts is to buy stock in Vincerx Pharma.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/26/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/24/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/22/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/22/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/21/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/19/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/18/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/17/2022

Latest Recommendations

  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/14/2022HC WainwrightInitiated CoverageBuy$25.00High
12/23/2021Cantor FitzgeraldInitiated CoverageOverweight$25.00High
12/17/2021Chardan CapitalReiterated RatingBuy$30.00Medium
12/14/2021SVB LeerinkReiterated RatingBuyHigh
11/1/2021SVB LeerinkInitiated CoverageOutperform$24.00High
9/13/2021LaidlawInitiated CoverageBuy$30.00Low
8/25/2021B. RileyInitiated CoverageBuy$26.00Medium
8/13/2021Chardan CapitalLower Price TargetBuy$33.00 ➝ $30.00High
1/6/2021Chardan CapitalInitiated CoverageBuy$33.00N/A
(Data available from 1/17/2017 forward)

News Sentiment Rating

0.46 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/21/2021
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/21/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
8/20/2021
  • 1 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
9/19/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/19/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
11/18/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
12/18/2021
  • 3 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
1/17/2022

Current Sentiment

  • 3 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Vincerx Pharma logo
Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops new therapies to address unmet medical needs for the treatment of cancer. The company's lead product candidate is VIP152 that is in Phase I clinical trials to treat solid tumors. Its preclinical stage product candidates include VIP217 for solid tumors; VIP236 to treat multiple solid tumors; VIP943 for the treatment of leukemia and myelodysplastic syndrome; and VIP924 for treating B-cell malignancies. Vincerx Pharma, Inc. was founded in 2019 is based in Palo Alto, California.
Read More

Today's Range

Now: $8.00
Low: $7.81
High: $8.20

50 Day Range

MA: $10.60
Low: $7.90
High: $14.34

52 Week Range

Now: $8.00
Low: $7.81
High: $26.75

Volume

521,375 shs

Average Volume

136,000 shs

Market Capitalization

$168.46 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Vincerx Pharma?

The following Wall Street analysts have issued research reports on Vincerx Pharma in the last year: B. Riley, Cantor Fitzgerald, Chardan Capital, HC Wainwright, Laidlaw, SVB Leerink LLC, and Zacks Investment Research.
View the latest analyst ratings for VINC.

What is the current price target for Vincerx Pharma?

6 Wall Street analysts have set twelve-month price targets for Vincerx Pharma in the last year. Their average twelve-month price target is $26.67, suggesting a possible upside of 233.3%. Chardan Capital has the highest price target set, predicting VINC will reach $30.00 in the next twelve months. SVB Leerink LLC has the lowest price target set, forecasting a price of $24.00 for Vincerx Pharma in the next year.
View the latest price targets for VINC.

What is the current consensus analyst rating for Vincerx Pharma?

Vincerx Pharma currently has 6 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe VINC will outperform the market and that investors should add to their positions of Vincerx Pharma.
View the latest ratings for VINC.

How do I contact Vincerx Pharma's investor relations team?

Vincerx Pharma's physical mailing address is 260 SHERIDAN AVENUE SUITE 400, PALO ALTO CA, 94306. The company's listed phone number is 650-800-6676. The official website for Vincerx Pharma is vincerapharma.com.